Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
ASNDCOPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly TransCon® CNP (navepegritide) in children with achondroplasia have been published in JAMA Pediatrics, a journal of the American Medical Association. In the publication, titled “Once-Weekly Navepegritide in Children with Achondroplasia: The ApproaCH Randomized Clinical Trial,” the authors report that treatment with TransCon CNP led to significantly higher annualized growth velocity (AGV) at Week 52 compared to placebo (primary endpoint), as well as improved lower-limb alignment and body proportionality and positive changes in health-related quality of life, with a safety and tolerability profile similar to placebo. The abstract can be accessed on the JAMA Pediatrics website.
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
ASND(NASDAQ:ASND) COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the American Society for Bone & Mineral Research being held in Seattle from September 5-8, 2025. These include a new analysis of pivotal trial data correlating improvements in leg bowing with improved physical functioning in children with achondroplasia treated with TransCon® CNP (navepegritide); the first medical congress presentation of clinical trial data for children with achondroplasia treated with TransCon CNP and TransCon hGH (lonapegsomatropin) combination therapy; and clinical trial data demonstrating the sustained improvements in skeletal dynamics in adults with hypoparathyroidism treated for 4 years with TransCon PTH (palopegteriparatide).
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
ASND(NASDAQ:ASND) COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time in Boston, Massachusetts.
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
ASNDB of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $216
ASNDIs Ascendis Pharma Gaining or Losing Market Support?
ASNDB of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $201
ASNDAscendis Pharma Announced FDA Acceptance For Priority Review Of New Drug Application For TransCon CNP For Children With Achondroplasia And Set Prescription Drug User Fee Act Goal Date Of Nov. 30, 2025 To Complete Review.
ASNDIf You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
ASNDAscendis Pharma's SKYTROFA Is Now Registered By Therapeutic Goods Administration For Treatment Of Paediatric Growth Hormone Deficiency
ASNDIf You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
ASNDAscendis Pharma Announces New Data Regarding Improvement In Growth And Bone Morphometry From Week 52 Of Its ApproaCH Trial Of TransCon CNP In Children With Achondroplasia.
ASNDAscendis Pharma Announces New Data From Week 214 Of Its Phase 2 Path Forward Trial Showing That Long-Term Treatment With TransCon PTH Continued To Provide A Durable Response In Adults With Hypoparathyroidism
ASNDCantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $200 Price Target
ASNDHere's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
ASNDAscendisTto Share Data From Hypoparathyroidism, Achondroplasia, And Growth Hormone Deficiency Programs During ESPE & ESE 2025
ASNDThis Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
ASNDMorgan Stanley Upgrades Ascendis Pharma to Overweight, Raises Price Target to $250
ASNDRBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $210
ASNDJP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $245
ASNDWedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $212
ASNDEvercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $280
ASNDA Glimpse of Ascendis Pharma's Earnings Potential
ASNDRBC Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $205
ASNDIf You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
ASNDAscendis Submits New Drug Application To FDA For TransCon CNP For Treatment Of Children With Achondroplasia.
ASNDLooking Into Ascendis Pharma's Recent Short Interest
ASNDHere's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
ASNDJP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
ASNDIf You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
ASNDCantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
ASNDWhy Is BioMarin Stock Trading Higher On Thursday?
ASNDBioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
ASNDEvercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $260
ASNDWhy Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
ASNDAscendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
Goldman Sachs Maintains Buy on Ascendis Pharma, Raises Price Target to $225
ASNDJP Morgan Maintains Overweight on Ascendis Pharma, Raises Price Target to $168
ASNDAscendis Pharma Authorized To Repurchase Up To $18.25M Shares
ASNDAscendis Pharma Q4 2024 GAAP EPS €(0.64) Beats €(1.07) Estimate, Sales €173.916M Beat €111.178M Estimate
ASNDLooking Into Ascendis Pharma's Recent Short Interest
ASNDReported Earlier, Ascendis Pharma Projects €364M In 2024 Revenue, Reports €655M In Cash, Highlights SKYTROFA And YORVIPATH Growth, And Prepares For Transcon CNP NDA Filing In Early 2025
ASNDAscendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
ASNDTD Cowen Maintains Buy on Ascendis Pharma, Lowers Price Target to $153
ASNDWedbush Reiterates Outperform on Ascendis Pharma, Maintains $181 Price Target
ASNDOppenheimer Maintains Outperform on Ascendis Pharma, Lowers Price Target to $180
ASNDCantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $170 Price Target
ASNDStifel Maintains Buy on Ascendis Pharma, Raises Price Target to $207
ASNDAscendis Sees FY24 Operating Expenses ~€600M
ASNDAscendis Q3 2024 Revenue $€57.8M Vs €48M Prior
ASND(ASND) - Analyzing Ascendis Pharma's Short Interest
ASND